Experimental Pharmacology
Research in the Masereeuw group is focused on understanding the pathways that can be pharmacologically triggered to enhance repair and regeneration processes after organ injury, aiming at elucidating novel bio-inspired therapeutic strategies.
The research can be roughly divided in two lines:
1. Disease modeling
Aims are to unravel the interactions between (therapeutic) molecules and biological systems in organ systems. For this, humanized in vitro systems are being applied that functionally mimic (patients) organs, which includes the use of innovative technologies for 3-dimensional organ cultures such as microfluidics (organs-on-chip technology). These experimental tools should aid in translating molecular interactions into therapeutic effects. Target organs currently involve (but are not restricted to) the kidney and the intestine, individually and combined, allowing studying the interaction between two organs when one of them fails.
2. Regenerative (nephro-)pharmacology
Aims are to develop novel therapeutic strategies to accelerate organ function recovery during failure and to gain insight in processes that determine the excretion of metabolic wastes and drugs by the kidneys to develop novel interventions for renal disease. The past years, novel renal tubular excretion pathways were identified, as well as regulatory pathways towards the transporters involved that can be pharmacologically triggered to improve function during kidney failure. The Masereeuw group has developed unique, patented, human renal cell lines with a high predictive value for drug and waste product transport and metabolism. These cell lines are used in the development of a bioartificial kidney, a kidney-on-a-chip device suitable for in vitro toxicity testing of chemical entities and drugs in development, and for studying the renal tubular secretion and reabsorption machinery.
Contact for internships
Prof. dr. Roos Masereeuw: R.Masereeuw@uu.nl
Dr. Silvia Mihăilă: S.Mihaila@uu.nl
Dr. Anne Metje van Genderen: A.M.vanGenderen@uu.nl
People
Name | Position | Additional info | |
Roos Masereeuw | Professor | ORCID: 0000-0002-1560-1074 | |
Silvia Mihăilă | Assistant professor |
| |
Anne Metje van Genderen | Assistant professor |
| |
Rolf Sparidans | Assistant professor |
| |
Dr. Quentin Faucher | Postdoc |
| |
Dr. Ronald van Gaal | Postdoc |
| |
Dr. Elena Sendino Garvà | Postdoc |
| |
Robine Janssen | PhD |
| |
Devon Barnes | PhD |
| |
Avra Madella | PhD |
| |
Ralph de Groot | PhD |
| |
Elianne Angela-Oosterom | PhD |
| |
Kate Liang | PhD |
| |
Jet Hartman | PhD |
| |
Jim Koldenhof | PhD |
| |
Monica Maselli | PhD |
| |
Faranak Heidari | PhD |
| |
Ann-Engelke Timm | PhD |
| |
Lena Heer | PhD |
| |
Leyla Sharafutdinova | PhD |
| |
Linda Gijzen | PhD |
| |
Puck Roos | PhD |
| |
Michelle Versluis | PhD |
| |
Ananya Singh | PhD |
| |
Catarina Antunes | PhD |
|
|
Roger Mora de la Serna | PhD |
| |
Nargis Khoso | Technician |
| |
Koen Westphal | Technician |
|
|
Alinda Berends | Technician |
| |
Dr. Thom van der Made | Scientific Coordinator Sector Plan Beta 2 Pharmaceutical Sciences |
|
Publications
Alumni
Name | Past/current position | Additional info | |
Marta GarcÃa Valverde | PhD/postdoc at Novartis, Basel, Switzerland | Shaping the kidney: Engineering advanced in vitro models for studying renal function in health and disease | |
Laura Giordano | PhD/post-doc | Exploring the Gut-Kidney Axis in Chronic Kidney Disease: In Vitro Insights into Interorgan Crosstalk | |
Dr. Sabbir Ahmed | PhD/Postdoc UMCU | The potential of protein-bound uremic toxins as biomarkers of kidney tubular function | |
Dr. Joao Ferreira Faria | PhD | The potential of renal proximal tubule cells for disease modeling and therapeutic interventions | |
Dr. Manoe Janssen | Senior scientist RadboudUMC |
| |
Dr. Yi Yang | Researcher at Chongqing hospital, China |
| Insights into protein-bound uremic toxins in proximal tubule cell senescence and kidney fibrosis |
Dr. Zhenguo Wang | Researcher at Guangzhou ľ¹Ï¸£ÀûÓ°ÊÓ, China | Intrahepatic cholangiocyte organoids for bile-duct tissue engineering and disease modelling
| |
Dr. Zulfan Zazuli | Assistant professor at the School of Pharmacy, Bandung Institute of Technology Bandung, Indonesia |
| Optimizing safety of cisplatin treatment – Utilizing pharmacogenomics to prevent nephrotoxicity |
Dr. Haysam Ahmed | Principal scientist, Slough, UK |
| |
Dr. Paul Jochems | Impact Developer at Avans ľ¹Ï¸£ÀûÓ°ÊÓ of Applied Sciences/Biotech Booster | Development, validation and application of a novel bioengineered intestinal tubule: the whey to future proteins | |
Dr. Milos Mihajlovic | Postdoc / Postdoc Italian Liver Foundation NPO | A next step towards bioartificial kidney preclinical safety evaluation | |
Dr. Rafael Lindoso | Postdoc / Head of laboratory in precision Nephrology at Bayer |
| |
Dr. Hossein Eslami Amirabadi | Postdoc/Co-founder AZAR innovations |
| |
Dr. Katja Jansen | PhD/Business Developer & Project Manager at Genewity | One Cell to Rule Them All; The Potential of Proximal Tubule Epithelial Cells in Regenerative Kidney Therapies for Uremic Toxin Removal | |
Dr. Amer Jamalpoor | PhD/Chief Scientific Officer Toxys | Investigating the pathophysiology and potential therapeutic approaches for nephropathic cystinosis
| |
Dr. Jitske Jansen | Postdoc/Group leader Drug Discovery and Target Validation Sequantrix | Innovative strategies to improve or replace renal proximal convoluted tubule function | |
Dr. Pedro Caetano-Pinto | PhD/Group leader Experimental Urology Universitätsmedizin Greifswald | The study of function and regulation of renal drug transporters in human proximal tubuleeEpithelial cells |